You will recall that Nplate is a thrombopoietin receptor agonist indicated for the treatment of low platelet counts in patients with immune thrombocytopenic purpura or ITP.
Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 60.3% to RMB30. 0 million (US$4. 4 million) in the first quarter of 2010, compared to RMB18. 7 million (US$2. 7 million) in the first quarter of 2009. ❋ Unknown (2010)
-- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 32. 7% to RMB89. 7 million ❋ Unknown (2010)
Dr. Ward is the lead investigator for clinical trials of new anticoagulants and thrombopoietin agonists at RNS. ❋ Unknown (2010)
Signaling of the thrombopoietin (THPO) receptor MPL is critical for the maintenance of hematopoietic stem cells (HSCs) and megakaryocytic differentiation. ❋ Daniel C Wicke (2010)
Milazzo L, Vulcano F, Pascuccio M, Macioce G, et al. (2008) Long-term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin-amplified in clinical grade serum-free culture. ❋ Sangeetha V. M Et Al. (2010)
K, Yoshino H, Ebihara Y, Yagasaki H, et al. (2000) Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. ❋ Sangeetha V. M Et Al. (2010)
-- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin ( "TPO") product, increased by 44.6% to RMB32. 1 million ❋ Unknown (2010)
Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. ❋ Unknown (2010)
Seita J, Ema H, Ooehara J, Yamazaki S, Tadokoro Y, et al. (2007) Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. ❋ Lina Han Et Al. (2009)
Boer AK, Los EL, Esselink MT, Vellenga E (2005) Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase. ❋ Lina Han Et Al. (2009)
It is a first-in-class thrombopoietin mimetic agent for the treatment of chronic immune thrombocytopenic purpura (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. ❋ Unknown (2009)
(Sigma, St. Louis, MO, USA) containing 40 ng/ml stem cell factor, 40 ng/ml FLT3, and 10 ng/ml thrombopoietin (all from CellGenix, Antioch, IL, USA) for at least 5 days before labeling, with the cell concentration kept at 1×10 ❋ Branislava Janic Et Al. (2009)
The primary endpoints of the interim study for presentation at ASH evaluated adverse event rates with long-term use of Nplate and incidence of antibody development to Nplate and/or thrombopoietin (TPO).
Ueda T, Tsuji K, Yoshino H, Ebihara Y, Yagasaki H, et al. (2000) Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. ❋ Amanda Kwant-Mitchell Et Al. (2009)
Bradley HL, Couldrey C, Bunting KD (2004) Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. ❋ Lina Han Et Al. (2009)